retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Agonism Based Therapies for | Current Cardiovascular Risk Reports retatrutide triple hormone receptor agonist

Common CPT Codes Office Visits (2021 E/M Guidelines) 9920299205 New patient visits 9921199215 Established patient visits Obesity Counseling 9940199404 Preventive counseling (commercial payers) G0447 Face-to-face obesity counseling (Medicare) Diabetes Self-Management Training G0108 Individual DSMT G0109 Group DSMT Prior Authorization & Payer Policy Requirements Most payers require prior authorization (PA) for GLP-1 medications

In May, VCU researchers published a study in JAMA Network Open that suggested breast cancer patients who used GLP-1s had better outcomes than those who didn't take the medications

Medications including Ozempic, Mounjaro, Wegovy, and Saxenda demonstrate significant results in facilitating weight loss and improving blood sugar regulation

Patients can remain on these medications indefinitely, and the clinical data supporting long-term use extends to multiple years

What to Ask Your Rheumatologist (and Your GLP-1 Provider) If you have lupus or RA and are considering a GLP-1 medication, a few questions are worth raising directly: With your rheumatologist: Is my disease currently stable enough to add a new medication

In 2025, that meant it was impossible for me to scroll through my feed without being visually assaulted by ingratiating marketing campaigns, encouraging me to shed those last few pesky pounds via drugs, specifically off-label GLP-1